Introduction
Glucagon-like peptide-1 receptor agonists are well-established type 2 diabetes (T2D) treatments. As variations among populations and culture might influence treatment effects, this post hoc analysis evaluates the efficacy and safety of once-weekly (OW) semaglutide in a Korean population.
Methods
Korean adults with T2D inadequately controlled on metformin included in a 30-week, phase 3a, international, multicentre trial (NCT03061214) compared OW subcutaneous semaglutide (0.5 mg and 1.0 mg) with once-daily sitagliptin (100 mg). Key endpoints included change in glycated haemoglobin (HbA
1c
) and body weight; additional endpoints assessed proportions of participants reaching targets of HbA
1c
< 7.0% and ≤ 6.5%, ≥ 5% weight loss, and a composite endpoint of HbA
1c
< 7.0% without severe/blood glucose-confirmed symptomatic hypoglycaemia and no weight gain.
Results
Korean participants (
n
= 110) showed a greater reduction in HbA
1c
and body weight with semaglutide 0.5 mg (–1.6%, –2.7 kg) and 1.0 mg (–1.8%, –4.8 kg) versus sitagliptin (–0.9%, 0.5 kg). HbA
1c
targets of < 7.0% and ≤ 6.5% were achieved by more participants treated with semaglutide 0.5 mg (80.0% and 60.0%, respectively) and 1.0 mg (87.5% and 67.5%, respectively) versus sitagliptin (54.3% and 25.7%, respectively); ≥ 5% weight loss was observed in 42.9% and 65.0% of participants treated with semaglutide 0.5 mg and 1.0 mg versus 0.0% with sitagliptin. The composite endpoint was achieved by 71.4%, 77.5%, and 31.4% of the population in the semaglutide 0.5 mg, 1.0 mg, and sitagliptin group, respectively. No new safety concerns were observed.
Conclusion
This analysis confirms efficacy and safety of OW semaglutide (0.5 and 1.0 mg) in a Korean population with T2D.
Clinical Trial Registration Number
NCT03061214.
Supplementary Information
The online version contains supplementary material available at 10.1007/s13300-023-01515-0.